GlassScriptPhysician profile
Manisha B Grover
NPI 1336311927
$1,699.06
in general payments reported to CMS, 2019-2025
30 companies · $23.69 in 2025
The $23.69 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $263 · 2021: $299 · 2022: $342 · 2023: $204 · 2024: $67.21 · 2025: $23.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $246.66 | 2019-2022 | |
| Mylan Specialty L.P. | $207.09 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $123.98 | 2019-2023 | Dificid, Zerbaxa, Recarbrio |
| Janssen Pharmaceuticals, INC | $121.25 | 2019-2024 | Xarelto |
| Pfizer INC. | $95.88 | 2019-2022 | |
| Abbvie INC. | $78.42 | 2021-2023 | |
| Ge Healthcare | $76.53 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $66.60 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $64.74 | 2019-2022 | |
| Biogen, INC. | $43.28 | 2021 | |
| Amgen INC. | $39.82 | 2019-2022 | |
| Dexcom, INC. | $37.67 | 2022-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $36.18 | 2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $29.61 | 2021-2023 | Vpriv |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $29.04 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $27.29 | 2019 | |
| Lilly USA, LLC | $26.45 | 2019-2021 | |
| Astellas Pharma US INC | $26.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.92 | 2019 | |
| Exact Sciences Corporation | $24.98 | 2023 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.69 | 2025 | Lifevest |
| Allergan, INC. | $16.93 | 2020 | |
| Glaxosmithkline, LLC. | $15.94 | 2023 | Boostrix, Shingrix |
| Amarin Pharma, INC. | $14.95 | 2020 | |
| Melinta Therapeutics, LLC | $14.86 | 2023 | Orbactiv, Kimyrsa, Rezzayo |
| Alexion Pharmaceuticals, INC. | $13.84 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.76 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $12.42 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.